Harvard Business Review

MARCH 28, 2012

This ongoing struggle raises an issue that is endemic in such acquisitions: In search of innovation, big companies often buy other companies whose most innovative days are almost at an end. An acquirer looking for innovation would have been likelier to try to buy Gateway, a company that is almost an after-thought now.

Innovation 13

Innovation Company Biotechnology CFO 13

Harvard Business Review

JULY 11, 2018

To focus on businesses that are closer in spirit to the prototypical high-tech startup, we used a variety of indicators: whether the firm was granted a patent, received VC investment, or operated in an industry that employs a high fraction of STEM workers. In light of this evidence, why do some VCs persist in betting on young founders?

Succession 15

Succession IPO Entrepreneur Biotechnology 15

Harvard Business Review

FEBRUARY 17, 2011

Venture capitalists are increasingly interested in emerging markets, and in working with local funds based in those markets (despite the fact that reverse innovation in venture capital seems counterintuitive). In effect, the VCs at Nadathur Holdings serve as the executive team for a miniature healthcare innovation ecosystem.

Marketing 15

Marketing Venture Capitalist Biotechnology IPO 15

Harvard Business Review

MAY 2, 2011

Without operating in the former, they won't be able to attain economies of scale; sans the latter, they're unlikely to continue developing state-of-the-art technologies. Another CEO of a fast-growing biotechnology venture, a Chinese-American entrepreneur, added that he wanted his company to be perceived as American rather than as Chinese.

Globalization 14

Globalization Marketing Venture Capitalist Biotechnology 14

Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. economy, expands America's global trade, and attracts foreign companies to base operations in the U.S.

Competitive Advantage 14

Competitive Advantage Globalization Development Intellectual Capital 14

Harvard Business Review

OCTOBER 26, 2011

Their behavior displays promising parallels to the early days of the biotechnology industry. When biotechnology startups like Genentech began to acquire other startups to retain their edge, pharmaceutical incumbents were forced to enter the acquisition melee to remain competitive. Click on the table below to see at full size.).

Energy 11

Energy Finance IPO Biotechnology 11

Harvard Business Review

JUNE 4, 2018

’s “once unchallenged preeminence in commerce, industry, science, and technological innovation is being overtaken by competitors throughout the world.” operational headquarters in Lexington, Massachusetts, which has been working with nearby Quincy College for the past several years.

Education 8

Education Company Biotechnology Human Capital 8

Harvard Business Review

JUNE 16, 2016

The Institute for Applied Cancer Science at MD Anderson (IACS) is exploring revolutionary new cures and the National Network for Manufacturing Innovation (NNMI) is working to revive the US production capacity. Innovating the Innovation Process. “But here, we can operate within the time frame of the next coffee break.”

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

OCTOBER 23, 2014

That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. They’re also sharing risk. The new business model has yet to solidify, and the leaders have yet to emerge. The positions are there for the taking. But not for long.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Harvard Business Review

FEBRUARY 3, 2015

Make you more innovative. Uzzi and another colleague, Jarrett Spiro, also discovered that this pattern held across sectors as disparate as the Broadway mu­sical industry and biotechnology. The sidebar “The Innovator’s Network Dilemma” presents convincing data that bears out this observation.

How To 8

How To Diversity Letter Learning-by-Doing 8

Harvard Business Review

MARCH 5, 2012

This tight connection between R&D, innovation, and production is present in sectors like biotechnology, advanced materials, and nanotechnology. Ironically, American manufactures often cannot find workers with the technical and vocational skills required in today's sophisticated manufacturing operations. The Right Policies.

Health Care 9

Health Care Biotechnology Industry Policies 9

Harvard Business Review

MARCH 30, 2017

We worked with a startup biotechnology company. an engineering culture, an operational culture, or a relational culture), we stifle the natural cognitive diversity in groups through the pressure to conform. It cannot be predicted or easily orchestrated. When we have a strong, homogenous culture (e.g.,

Diversity 8

Diversity Team Biotechnology Execution 8

Harvard Business Review

SEPTEMBER 11, 2014

For example, a wide variety of clean technologies (including wind, solar, and hydrogen) are vying to power vehicles and cities at the same time that a wide variety of medical technologies (chemical, biotechnological, genomic, and robotic) are being developed to treat diseases. Customers Innovation Technology'

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22